Deenan Pillay
Deenan Pillay
Unknown affiliation
Verified email at
Cited by
Cited by
2011 update of the drug resistance mutations in HIV-1
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ...
Topics in antiviral medicine 19 (4), 156, 2011
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
DE Bennett, RJ Camacho, D Otelea, DR Kuritzkes, H Fleury, M Kiuchi, ...
PloS one 4 (3), e4724, 2009
2017 update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 24 (4), 132, 2016
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
MS Hirsch, HF Günthard, JM Schapiro, FB Vézinet, B Clotet, SM Hammer, ...
Clinical Infectious Diseases 47 (2), 266-285, 2008
Digital technologies in the public-health response to COVID-19
J Budd, BS Miller, EM Manning, V Lampos, M Zhuang, M Edelstein, ...
Nature medicine 26 (8), 1183-1192, 2020
Update of the Drug Resistance Mutations in HIV-1: 2005
VA Johnson, F Brun-Vézinet, B Clotet, B Conway, D Pillay, J Schapiro, ...
Top. HIV Med 14 (3), 125-130, 2006
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008
BG Gazzard, J Anderson, A Babiker, M Boffito, G Brook, G Brough, ...
HIV medicine 9 (8), 563-608, 2008
Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global …
RK Gupta, MR Jordan, BJ Sultan, A Hill, DHJ Davis, J Gregson, ...
The Lancet 380 (9849), 1250-1258, 2012
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …
L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ...
The Lancet infectious diseases 11 (5), 363-371, 2011
Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study
A Banerjee, L Pasea, S Harris, A Gonzalez-Izquierdo, A Torralbo, ...
The Lancet 395 (10238), 1715-1725, 2020
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
RW Shafer, SY Rhee, D Pillay, V Miller, P Sandstrom, JM Schapiro, ...
Aids 21 (2), 215-223, 2007
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ...
PLoS medicine 2 (4), e112, 2005
Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle-and high-income countries
BJA: British Journal of Anaesthesia 117 (5), 601-609, 2016
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B. 1.1. 7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study
D Frampton, T Rampling, A Cross, H Bailey, J Heaney, M Byott, R Scott, ...
The Lancet infectious diseases 21 (9), 1246-1256, 2021
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression …
RK Gupta, J Gregson, N Parkin, H Haile-Selassie, A Tanuri, LA Forero, ...
The Lancet infectious diseases 18 (3), 346-355, 2018
Update of the drug resistance mutations in HIV-1: March 2013
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ...
Topics in antiviral medicine 21 (1), 6, 2013
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and …
RK Gupta, A Hill, AW Sawyer, A Cozzi-Lepri, V von Wyl, S Yerly, VD Lima, ...
The Lancet infectious diseases 9 (7), 409-417, 2009
Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups
S Hué, D Pillay, JP Clewley, OG Pybus
Proceedings of the National Academy of Sciences 102 (12), 4425-4429, 2005
HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy
S Hué, JP Clewley, PA Cane, D Pillay
Aids 18 (5), 719-728, 2004
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
J Gregson, M Tang, N Ndembi, RL Hamers, SY Rhee, VC Marconi, ...
The Lancet infectious diseases 16 (5), 565-575, 2016
The system can't perform the operation now. Try again later.
Articles 1–20